CATX

Perspective Therapeutics, Inc.
$2.81
+0.04 (+1.63%)
Mkt Cap 320.47M
Volume 2,024,731
52W Range 1.96-6.16
Sector Healthcare
Beta 1.80
EPS (TTM) -1.56 USD
P/E Ratio -1.96
Revenue (TTM) 366,000 USD
Rev Growth (5Y) -35.3%
EPS Growth (5Y) N/A
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Stable Earnings Power
11.5 / 100 pillar composite (overridden)
Steady, predictable earnings power — graded A–F vs. similar companies.

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 0 1.45M 1.43M 7.10M 10.79M 10.05M 9.68M 7.31M 5.92M 4.76M 4.77M 4.61M
Net Income (103.12M) (79.28M) (46.51M) (14.67M) (7.27M) (3.19M) (3.27M) (4.85M) (6.70M) (6.16M) (4.71M) (3.68M)
EPS -1.40 -1.23 -0.85 -0.27 -0.50 -0.06 -0.05 -0.07 -0.12 -0.11 -0.09 -0.07
Free Cash Flow (95.23M) (72.71M) (37.98M) (10.68M) (7.98M) (3.22M) (3.91M) (5.49M) (6.05M) (6.26M) (4.36M) (3.65M)
FCF / Share -1.29 -1.13 -0.69 -0.19 -0.56 -0.06 -0.06 -0.08 -0.11 -0.11 -0.08 -0.07
Operating CF (82.48M) (18.29M) (36.91M) (10.40M) (7.71M) (2.84M) (3.64M) (5.05M) (5.71M) (5.71M) (3.88M) (3.52M)
Total Assets 266.97M 341.10M 97.89M 58.09M 64.44M 15.51M 8.70M 9.42M 7.46M 12.27M 18.10M 23.00M
Total Debt 3.25M 4.06M 2.55M 524,000 524,000 897,000 1.00M 0 0 0 0 0
Cash & Equiv 30.63M 61.58M 9.24M 20.99M 55.89M 9.59M 2.39M 5.33M 2.60M 5.93M 10.14M 5.23M
Book Value 207.03M 290.67M 75.18M 54.64M 61.28M 12.77M 5.72M 7.68M 5.03M 10.60M 16.40M 20.78M
Return on Equity -0.50 -0.27 -0.62 -0.27 -0.12 -0.25 -0.57 -0.63 -1.33 -0.58 -0.29 -0.18
CATX News
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026
Sep 11, 2026 02:00 AM · globenewswire.com
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026
Sep 11, 2026 02:00 AM · globenewswire.com
Perspective Therapeutics: 'Strong Buy' On Bamzireotide Navoxetan Reinforced Data And Phase 3 Plans
Sep 01, 2026 02:23 PM · seekingalpha.com
Dimensional Fund Advisors LP Acquires 358,540 Shares of Perspective Therapeutics, Inc. $CATX
Aug 13, 2026 11:37 PM · defenseworld.net
Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?
Aug 04, 2026 06:41 AM · zacks.com
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Aug 03, 2026 07:35 AM · zacks.com
Perspective Therapeutics, Inc. $CATX Shares Bought by Avidity Partners Management LP
Jul 31, 2026 11:44 PM · defenseworld.net
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results
Jul 31, 2026 02:30 AM · globenewswire.com
Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Jul 29, 2026 06:56 AM · zacks.com
Ally Bridge Group NY LLC Makes New Investment in Perspective Therapeutics, Inc. $CATX
Jul 28, 2026 11:45 PM · defenseworld.net